AnaptysBio Stock Down as Eczema Study Fails to Meet Goals

Shares of AnaptysBio, Inc. (ANAB) , a clinical-stage biotechnology company, plunged 32.8% on Dec. 11 after it announced that the phase IIb study of pipeline candidate, ANB032, a BTLA agonist, was unsuccessful.Consequently, ANAB discontinued any further investment in this asset.AnaptysBio has lost 27.6% so far this year compared with the industry’s decline of 8.1%.Image Source: Zacks Investment ResearchMore on ANAB’s Study FailureThe ARISE-AD study evaluated the efficacy, safety, tolerability, pharmacokineti ...